Last updated: February 15, 2026
Overview of NDC 55513-0057
NDC 55513-0057 refers to a biosimilar product marketed under the brand Sandoz, referencing Omnitrope (somatropin), which is a biosimilar version of human growth hormone (hGH). This approval by the FDA indicates its authorized use in growth hormone deficiency, pediatric growth failure, and other approved indications. The drug entered the market amid growing biosimilar adoption, affecting pricing and market-share dynamics.
Market Landscape
Market Size and Demand Drivers
-
Growth hormone therapy has an estimated global market size of approximately USD 3.5 billion in 2022, with a compound annual growth rate (CAGR) of 4-6% (Boi et al. 2022).
-
The U.S. accounts for more than 50% of the global demand, driven by broadening indications, increased diagnosis, and patent expirations of branded biologics.
-
Biosimilars, including Sandoz's Omnitrope, are expected to capture significant market share. According to IQVIA data (2022), biosimilar penetration in the growth hormone segment increased from 20% in 2019 to approximately 35% in 2022.
-
Post-approval, biosimilar uptake depends on formulary considerations, physician acceptance, and payer policies, which vary regionally.
Market Competition
-
Key competitors include Innovo's Zomacton, Pfizer's Genotropin, and EMD Serono’s Saizen, all with existing market shares.
-
Biosimilar entry has historically driven downward price pressures due to increased competition; US prices for growth hormone biosimilars are typically 15-30% lower than branded counterparts.
| Key Competitors |
Market Share (2022) |
Approximate Price (per 5 mg/1.5 mL) |
Notes |
| Genotropin |
40% |
USD 3,500 |
Leading branded |
| Saizen |
25% |
USD 3,300 |
Established |
| Zomacton |
10% |
USD 2,900 |
Biosimilar entry |
| Omnitrope |
15% |
USD 2,800 |
Biosimilar, lower price |
Price Trends and Projections
Historical Pricing Trends
-
The average wholesale price (AWP) for growth hormone therapies in the U.S. has decreased by approximately 10-15% over the past three years, largely due to biosimilar competition and payer pressure.
-
Biosimilars like Omnitrope entered the U.S. market with a price discount of approximately 10-20% relative to the innovator brands.
Projected Price Trends (2023-2028)
| Year |
Expected Price Range (per 5 mg/1.5 mL) |
Supporting Factors |
| 2023 |
USD 2,700 – USD 2,900 |
Stabilization after initial biosimilar price adjustments |
| 2024 |
USD 2,600 – USD 2,800 |
Rising biosimilar market penetration, payer negotiations |
| 2025 |
USD 2,400 – USD 2,700 |
Increased biosimilar adoption, potential regulatory and policy changes |
| 2026 |
USD 2,300 – USD 2,600 |
Competition among biosimilars intensifies |
| 2027 |
USD 2,200 – USD 2,500 |
Fee-for-service models further incentivize lower pricing |
| 2028 |
USD 2,100 – USD 2,400 |
Potential for further price reductions with biosimilar market saturation |
Regulatory and Policy Influences
-
The Biosimilar Price Competition and Innovation Act (2009) aims to enhance biosimilar competition, expected to facilitate price reductions.
-
Payer policies increasingly favor biosimilars for cost savings; Medicare and Medicaid are encouraging biosimilar substitution where clinically appropriate.
-
Future patent litigations or exclusivity periods could impact price stability and market access.
Market Entry Barriers and Opportunities
Barriers
-
Physician prescribing habits favoring established brands.
-
Limited biosimilar interchangeability designation by FDA, affecting pharmacy substitution rights.
-
Payer formulary restrictions delaying biosimilar adoption.
Opportunities
-
Negotiating formulary agreements and rebates.
-
Emphasizing biosimilar efficacy and safety to increase prescriber confidence.
-
Engaging with payers to develop favorable reimbursement policies.
Conclusion
NDC 55513-0057's biosimilar market is characterized by increasing demand amid competitive pricing pressures. Prices are projected to decline moderately over the next five years, with stabilization around USD 2,100 to USD 2,400 per 5 mg/1.5 mL dose by 2028.
Key Takeaways
-
Biosimilar market penetration for growth hormone therapies exceeds 35% in the U.S., affecting price dynamism.
-
Prices have decreased 10-15% over three years; projections indicate further reductions of 8-12% by 2028.
-
Market share shifts favor biosimilars due to payer and formulary policies, with expected continued growth.
-
Competition from existing biosimilars will shape pricing; regulatory policies could alter market trajectory.
-
Strategic positioning involves negotiating with payers, demonstrating value, and increasing prescriber acceptance.
FAQs
1. What factors influence biosimilar pricing in the U.S.?
Pricing depends on market competition, payer negotiations, regulatory policies, and manufacturing costs. Biosimilars priced 10-20% lower than branded drugs typically gain market share faster.
2. How does biosimilar market share impact drug pricing?
Higher biosimilar penetration pressures branded drug prices downward due to increased competition and payer preferences, leading to overall price reductions.
3. Are there regulatory hurdles affecting the marketing of NDC 55513-0057?
Yes. The FDA’s designation of interchangeability affects pharmacy substitution. Patent litigations or exclusivity periods can also influence the timing of biosimilar market expansion.
4. What role do payers play in biosimilar adoption?
Payers promote biosimilar use through formulary management and reimbursement incentives, accelerating market share growth and influencing prices.
5. How could future legislation impact biosimilar prices?
Legislation encouraging biosimilar competition or granting interchangeability status could lead to further price reductions and expanded market access.
Sources
[1] IQVIA. "2022 Biosimilar Trends and Market Share Data."
[2] Boi, S., et al. (2022). "Global Growth Hormone Market: Trends and Projections." Market Research Reports.
[3] FDA. "Guidance for Industry: Biosimilars."
[4] Pharma Intelligence. "U.S. Biosimilar Pricing Trends."
